Inspire Medical Systems, Inc. (INSP) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $41.37 (+0.68%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Shagun Singh | RBC Capital | $56.00 | +35.4% |
| Mar 5, 2026 | Jonathan Block | Stifel Nicolaus | $85.00 | +105.5% |
| Jan 22, 2026 | Richard Newitter | Truist Financial | $96.00 | +132.1% |
| Jan 22, 2026 | Daniel Markowitz | Evercore ISI | $125.00 | +202.2% |
| Jan 8, 2026 | Richard Newitter | Truist Financial | $120.00 | +190.1% |
| Dec 23, 2025 | Danielle Antalffy | UBS | $91.00 | +120.0% |
| Nov 24, 2025 | Jonathan Block | Stifel Nicolaus | $110.00 | +165.9% |
| Nov 4, 2025 | GAAP EPS | Piper Sandler | $135.00 | +226.3% |
| Nov 4, 2025 | Anthony Petrone | Mizuho Securities | $110.00 | +165.9% |
| Nov 4, 2025 | Lawrence Biegelsen | Wells Fargo | $90.00 | +117.5% |
| Oct 24, 2025 | Jonathan Block | Stifel Nicolaus | $100.00 | +141.7% |
| Oct 10, 2025 | Shagun Singh | RBC Capital | $150.00 | +262.6% |
| Sep 22, 2025 | Danielle Antalffy | UBS | $89.00 | +115.1% |
| Sep 2, 2025 | Daniel Markowitz | Evercore ISI | $150.00 | +262.6% |
| Aug 5, 2025 | Danielle Antalffy | UBS | $230.00 | +456.0% |
| May 6, 2025 | Kallum Titchmarsh | Morgan Stanley | $200.00 | +383.4% |
| Apr 15, 2025 | Shagun Singh | RBC Capital | $215.00 | +419.7% |
| Nov 5, 2024 | Adam Maeder | Piper Sandler | $260.00 | +528.5% |
| Nov 5, 2024 | David Rescott | Robert W. Baird | $252.00 | +509.1% |
| Oct 15, 2024 | David Rescott | Robert W. Baird | $240.00 | +480.1% |
Top Analysts Covering INSP
INSP vs Sector & Market
| Metric | INSP | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.58 | 2.24 | 2.40 |
| Analyst Count | 26 | 8 | 19 |
| Target Upside | +33.3% | +11475.0% | +17.1% |
| P/E Ratio | 9.21 | 3.90 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $901M | $962M | $1.01B | 12 |
| 2027-03-31 | $208M | $224M | $232M | 4 |
| 2027-06-30 | $228M | $245M | $254M | 4 |
| 2027-09-30 | $239M | $257M | $266M | 5 |
| 2027-12-31 | $285M | $307M | $318M | 4 |
| 2028-03-31 | $233M | $251M | $260M | 3 |
| 2028-06-30 | $257M | $276M | $286M | 3 |
| 2028-09-30 | $269M | $289M | $299M | 5 |
| 2028-12-31 | $326M | $351M | $364M | 3 |
| 2029-12-31 | $1.16B | $1.25B | $1.30B | 4 |
| 2030-12-31 | $1.25B | $1.33B | $1.39B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.95 | $1.86 | $2.22 | 9 |
| 2027-03-31 | $0.09 | $0.10 | $0.11 | 3 |
| 2027-06-30 | $0.40 | $0.44 | $0.46 | 5 |
| 2027-09-30 | $0.57 | $0.63 | $0.66 | 3 |
| 2027-12-31 | $1.10 | $1.21 | $1.27 | 6 |
| 2028-03-31 | $0.47 | $0.51 | $0.54 | 4 |
| 2028-06-30 | $0.65 | $0.72 | $0.75 | 6 |
| 2028-09-30 | $0.67 | $0.74 | $0.77 | 4 |
| 2028-12-31 | $0.79 | $0.88 | $0.92 | 7 |
| 2029-12-31 | $3.64 | $3.98 | $4.20 | 2 |
| 2030-12-31 | $4.46 | $4.87 | $5.14 | 2 |
Frequently Asked Questions
What is the analyst consensus for INSP?
The consensus among 26 analysts covering Inspire Medical Systems, Inc. (INSP) is Hold with an average price target of $91.33.
What is the highest price target for INSP?
The highest price target for INSP is $310.00, set by Adam Maeder at Piper Sandler on 2022-05-04.
What is the lowest price target for INSP?
The lowest price target for INSP is $56.00, set by Shagun Singh at RBC Capital on 2026-04-14.
How many analysts cover INSP?
26 analysts have issued ratings for Inspire Medical Systems, Inc. in the past 12 months.
Is INSP a buy or sell right now?
Based on 26 analyst ratings, INSP has a consensus rating of Hold (2.58/5) with a +33.3% upside to the consensus target of $91.33.
What are the earnings estimates for INSP?
Analysts estimate INSP will report EPS of $1.86 for the period ending 2026-12-31, with revenue estimated at $962M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.